| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J J He, S L Hu, Y M Li, Y Zhuang, H S Zheng, G L Zhu, J Ji. Pharmacoeconomic Evaluation Study On Preoperative Treatment Of Acromegaly With Somatostatin Analogues In Shanghai. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. vol 17. issue 7. 2016-06-10. PMID:27202689. |
pharmacoeconomic evaluation study on preoperative treatment of acromegaly with somatostatin analogues in shanghai. |
2016-06-10 |
2023-08-13 |
Not clear |
| Djordje Marina, Pia Burman, Marianne Klose, Olivera Casar-Borota, Raúl M Luque, Justo P Castaño, Ulla Feldt-Rasmusse. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 25. issue 5. 2016-06-09. PMID:26188991. |
truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--observations in two patients with acromegaly and severe headache. |
2016-06-09 |
2023-08-13 |
Not clear |
| Djordje Marina, Pia Burman, Marianne Klose, Olivera Casar-Borota, Raúl M Luque, Justo P Castaño, Ulla Feldt-Rasmusse. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 25. issue 5. 2016-06-09. PMID:26188991. |
somatotropinomas have unique "fingerprints" of somatostatin receptor (sst) expression, which are targets in treatment of acromegaly with somatostatin analogues (ssas). |
2016-06-09 |
2023-08-13 |
Not clear |
| Shlomo Melme. New therapeutic agents for acromegaly. Nature reviews. Endocrinology. vol 12. issue 2. 2016-05-31. PMID:26610414. |
the currently available somatostatin receptor ligands (srls) and growth hormone (gh) antagonists are used to control levels of gh and insulin-like growth factor 1 (igf-1) in patients with acromegaly. |
2016-05-31 |
2023-08-13 |
Not clear |
| Christian J Strasburger, Niki Karavitaki, Sylvère Störmann, Peter J Trainer, Ilonka Kreitschmann-Andermahr, Michael Droste, Márta Korbonits, Berit Feldmann, Kathrin Zopf, Violet Fazal Sanderson, David Schwicker, Dana Gelbaum, Asi Haviv, Martin Bidlingmaier, Nienke R Biermas. Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. European journal of endocrinology. vol 174. issue 3. 2016-05-18. PMID:26744896. |
patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. |
2016-05-18 |
2023-08-13 |
human |
| Christian J Strasburger, Niki Karavitaki, Sylvère Störmann, Peter J Trainer, Ilonka Kreitschmann-Andermahr, Michael Droste, Márta Korbonits, Berit Feldmann, Kathrin Zopf, Violet Fazal Sanderson, David Schwicker, Dana Gelbaum, Asi Haviv, Martin Bidlingmaier, Nienke R Biermas. Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. European journal of endocrinology. vol 174. issue 3. 2016-05-18. PMID:26744896. |
long-acting somatostatin analogues delivered parenterally are the most widely used medical treatment in acromegaly. |
2016-05-18 |
2023-08-13 |
human |
| A Valea, M Carsote, C Ghervan, C Georgesc. Glycemic profile in patients with acromegaly treated with somatostatin analogue. Journal of medicine and life. vol 8 Spec Issue. 2016-05-02. PMID:26361517. |
glycemic profile in patients with acromegaly treated with somatostatin analogue. |
2016-05-02 |
2023-08-13 |
Not clear |
| Silvia Vandeva, Maria Yaneva, Emil Natchev, Atanaska Elenkova, Krasimir Kalinov, Sabina Zachariev. Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by Acromegaly Quality of Life (AcroQoL) Questionnaire. Endocrine. vol 49. issue 3. 2016-04-25. PMID:25561370. |
the use of somatostatin analog (ssa) was associated with worse personal relations scores, while higher igf-1 index predicted worse appearance scores in patients with active acromegaly. |
2016-04-25 |
2023-08-13 |
Not clear |
| N G Mokrysheva, E O Mamedova, E A Pigarova, Yu A Berezkina, A V Vorontsov, V N Azizyan, A Yu Grigoriev, T R Alekseeva, M A Kutin, A V Kochatkov, L Ya Rozhinskay. [Multiple endocrine neoplasia type 1 syndrome with three classical components and chiasm glioma: specific features of target organ lesions and a clinical observation]. Terapevticheskii arkhiv. vol 87. issue 12. 2016-04-21. PMID:27035001. |
which have been initially regarded as epileptic seizures, after the use of sustained-release somatostatin analogues for the treatment of acromegaly. |
2016-04-21 |
2023-08-13 |
Not clear |
| Kate McKeag. Pasireotide in Acromegaly: A Review. Drugs. vol 75. issue 9. 2016-04-19. PMID:26017304. |
pasireotide (signifor(®), signifor(®) lar) is a somatostatin analogue recently approved for the treatment of acromegaly. |
2016-04-19 |
2023-08-13 |
Not clear |
| Kate McKeag. Pasireotide in Acromegaly: A Review. Drugs. vol 75. issue 9. 2016-04-19. PMID:26017304. |
similarly, in a 6-month, phase iii trial in patients with acromegaly inadequately controlled with somatostatin analogues for at least 6 months, the efficacy of pasireotide 40 or 60 mg was superior to that of continued octreotide 30 mg or lanreotide autogel 120 mg (each drug was administered once every 28 days) with regard to biochemical control. |
2016-04-19 |
2023-08-13 |
Not clear |
| Kate McKeag. Pasireotide in Acromegaly: A Review. Drugs. vol 75. issue 9. 2016-04-19. PMID:26017304. |
thus, in the treatment of acromegaly, pasireotide may be a more effective somatostatin analogue than other approved agents of the same class; however, the increased risk of hyperglycaemia needs to be considered and proactively managed. |
2016-04-19 |
2023-08-13 |
Not clear |
| Uma Rai, Thilini R Thrimawithana, Celine Valery, Simon A Youn. Therapeutic uses of somatostatin and its analogues: Current view and potential applications. Pharmacology & therapeutics. vol 152. 2016-04-01. PMID:25956467. |
somatostatin agonists are established in the treatment of acromegaly with recently approved indications in the therapy of neuroendocrine tumours. |
2016-04-01 |
2023-08-13 |
Not clear |
| R A Dumbell, F Scherbarth, V Diedrich, H A Schmid, S Steinlechner, P Barret. Somatostatin Agonist Pasireotide Promotes a Physiological State Resembling Short-Day Acclimation in the Photoperiodic Male Siberian Hamster (Phodopus sungorus). Journal of neuroendocrinology. vol 27. issue 7. 2016-03-29. PMID:25950084. |
administration of pasireotide, a long-acting somatostatin receptor agonist developed for the treatment of acromegaly, to male hamsters under a long-day (ld) photoperiod produced a body weight loss. |
2016-03-29 |
2023-08-13 |
Not clear |
| A Comunello, F Dassie, C Martini, E De Carlo, R Mioni, M Battocchio, A Paoletta, F Fallo, R Vettor, P Maffe. Heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues. Pituitary. vol 18. issue 4. 2016-03-21. PMID:25261332. |
heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues. |
2016-03-21 |
2023-08-13 |
Not clear |
| V S Nunes, J M S Correa, M E S Puga, E M K Silva, C L Boguszewsk. Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system. Pituitary. vol 18. issue 4. 2016-03-21. PMID:25261979. |
preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the grade system. |
2016-03-21 |
2023-08-13 |
Not clear |
| V S Nunes, J M S Correa, M E S Puga, E M K Silva, C L Boguszewsk. Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system. Pituitary. vol 18. issue 4. 2016-03-21. PMID:25261979. |
whether the preoperative use of somatostatin analogues (sa) improves surgical outcomes in acromegaly is still a matter of debate. |
2016-03-21 |
2023-08-13 |
Not clear |
| Esra Hatipoglu, Selma Bozcan, Pinar Kadiogl. Discontinuation of somatostatin analogs while acromegaly is in long-term remission. Pituitary. vol 18. issue 4. 2016-03-21. PMID:25301076. |
discontinuation of somatostatin analogs while acromegaly is in long-term remission. |
2016-03-21 |
2023-08-13 |
Not clear |
| Esra Hatipoglu, Selma Bozcan, Pinar Kadiogl. Discontinuation of somatostatin analogs while acromegaly is in long-term remission. Pituitary. vol 18. issue 4. 2016-03-21. PMID:25301076. |
we aimed to evaluate the disease activity of medically controlled patients with acromegaly after withdrawal of somatostatin receptor ligands (srl). |
2016-03-21 |
2023-08-13 |
Not clear |
| Ludovica F S Grasso, Renata S Auriemma, Rosario Pivonello, Annamaria Cola. Adverse events associated with somatostatin analogs in acromegaly. Expert opinion on drug safety. vol 14. issue 8. 2016-03-21. PMID:26184380. |
adverse events associated with somatostatin analogs in acromegaly. |
2016-03-21 |
2023-08-13 |
Not clear |